A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

Luís F. Moita; Timothy E. Sweeney; Pedro Póvoa

doi:10.1007/s00134-022-06823-w

A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

Luís F. Moita, Timothy E. Sweeney, Pedro Póvoa^*

^*Corresponding author for this work

KI, OUH, Research unit of Clinical Epidemiology (Odense)

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Journal	Intensive Care Medicine
Volume	48
Issue number	9
Pages (from-to)	1206-1207
ISSN	0342-4642
DOIs	https://doi.org/10.1007/s00134-022-06823-w
Publication status	Published - Sept 2022

Keywords

Cross Infection/diagnosis
Hospitals
Humans

Documents & Links

10.1007/s00134-022-06823-w

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{4c86bb500650488ab534e7c3fde90a17,

title = "A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections",

keywords = "Cross Infection/diagnosis, Hospitals, Humans",

author = "Moita, {Lu{\'i}s F.} and Sweeney, {Timothy E.} and Pedro P{\'o}voa",

note = "Funding Information: LFM—None to declare. TES—employee of and shareholder in Inflammatix, Inc. PP—received fees for lecture from Gilead and Pfizer, consulting from MSD and Sanofi and unrestricted research grant from Abionic. ",

year = "2022",

month = sep,

doi = "10.1007/s00134-022-06823-w",

language = "English",

volume = "48",

pages = "1206--1207",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer Science+Business Media",

number = "9",

}

TY - JOUR

T1 - A new possibility

T2 - gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

AU - Moita, Luís F.

AU - Sweeney, Timothy E.

AU - Póvoa, Pedro

N1 - Funding Information: LFM—None to declare. TES—employee of and shareholder in Inflammatix, Inc. PP—received fees for lecture from Gilead and Pfizer, consulting from MSD and Sanofi and unrestricted research grant from Abionic.

PY - 2022/9

Y1 - 2022/9

KW - Cross Infection/diagnosis

KW - Hospitals

KW - Humans

U2 - 10.1007/s00134-022-06823-w

DO - 10.1007/s00134-022-06823-w

M3 - Editorial

C2 - 35916912

AN - SCOPUS:85135354217

SN - 0342-4642

VL - 48

SP - 1206

EP - 1207

JO - Intensive Care Medicine

JF - Intensive Care Medicine

IS - 9

ER -